Navigation Links
Spelling out cancer on the nanoscale

Tumors start small and stay quiet, yet their intentions are clearly spelled out internally, if we could only read them. No matter how small, every tumor reveals its identity in tiny amounts of abnormally expressed proteins called oncoproteins. Being able to read trace oncoprotein levels from early-stage tumors would speak volumes to physicians and cancer researchers. Enter nano-fluidics and the art of reading a lot from very little.

Researchers led by Dean Felsher at Stanford University School of Medicine, and bioengineers at Cell Biosciences in Palo Alto, collaborated to develop an automated, high-throughput, nano-fluidic system that was able to measure the levels of three oncoproteins: MYC, BCL2, and AKT, in tiny samples drawn as very fine needle aspirates from hematopoetic tumor cells in preclinical transgenic mouse models. The nano-fluidic system physically separates the proteins in very small capillary tubes and then uses antibodies for protein detection. It was also tested on human lymphoma samples.

In previous work, the Felsher group had shown that inactivating MYC induces sustained tumor regression in mice. The researchers decided to test their conditional model of MYC-induced lymphoma by using their nano-fluidic system to quickly measure the impact of targeted protein inhibitors in mice. A series of fine needle-aspirated samples was analyzed, confirming a decrease in oncoprotein levels.

The new nano-fluidic system was also tested on human tumors by measuring the levels of MYC, BCL2, ERK, and AKT proteins in the lymph nodes obtained from patients with Burkitt’s, mantle cell, or follicular lymphoma. The nano-fluidic system reported that MYC was overexpressed in Burkitt’s, while BCL2 was overexpressed in mantle cell and follicular lymphoma patients. In parallel, traditional Western blots were performed to confirm BCL-2 and MYC levels.

"Our strategy can be used to repetitively and quickly assess the levels of oncopro teins in cancer cells grown in the laboratory and in human patients," says Felsher. "It may prove useful for the early detection of cancer, and for monitoring patients?responses during their treatment, allowing clinicians to tailor treatments to individual patients. Finally, we provide a high throughput method to identify if new cancer drugs are effective at targeting specific oncoproteins."
'"/>

Source:American Society for Cell Biology


Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
3. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Mitochondrial DNA mutations play significant role in prostate cancer
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. BRCA1 causes ovarian cancer through indirect, biochemical route
9. Researchers identify target for cancer drugs
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. First atlas of key brain genes could speed research on cancer, neurological diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... (PRWEB) , ... June 28, ... ... Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) simulation and analysis ... and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing users to easily ...
(Date:6/28/2017)... ... June 28, 2017 , ... Studies indicate that replacing damaged brain cells ... for Parkinson’s disease. But what has not been determined is the optimal stage during ... best results. , A new study coming out of Singapore, recently published in STEM ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... first brain mirroring wellness product via Kickstarter campaign on June 15th to fund ... already pre-ordered the B2v2, exceeding the original Kickstarter goal by more than 150% ...
(Date:6/27/2017)... ... June 27, 2017 , ... According to a recent report ... do not have negative short- or long-term effects on benthic communities. , ... (PCBs) located at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in ...
Breaking Biology Technology: